Special Report: MGC Pharma’s flagship epilepsy drug CannEpil will be the subject of yet another clinical trial after Australia’s ethics body approved a new study. MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC … Continue reading Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug